No Data
No Data
Xianruida Medical-B (06669): Application for registration of coronary hypertension balloon dilatation catheter pterygium was approved by China Drug Administration
Xianruida Medical-B (06669) issued an announcement. On March 20, 2024, the Group received China's national pharmaceuticals...
Xianruida Medical-B (06669.HK)'s annual adjusted net profit of $42.435 million increased 22.1% year-on-year
On March 25, Gelonghui | Xianruida Medical-B (06669.HK) issued an announcement. The stable and favorable state of production and research directly led to a rapid increase in annual revenue. For the year ended 31 December 2023, the company's revenue was approximately RMB 473.8 million, an increase of approximately 19.8% over the previous year. The company's core products, AcoArt Orchid & Dhalia and AcoArt Tulip & Litos, became the company's core revenue sources. The adjusted net profit during the year was $42.435 million, an increase of 22.1% over the previous year. Group as of 202312
ACOTEC-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Xianruida Medical-B (06669.HK) held a board meeting on March 25 to consider and approve the annual results
Glonghui, March 13 | Xianruida Medical-B (06669.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the audited annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider payment of a final dividend (if any).
Acotec Scientific's Peridge Catheter Gets China Approval
Acotec Scientific Holdings (HKG:6669) obtained registration approval from China's National Medical Products Administration for Peridge, a peripheral scoring balloon dilatation catheter. The device is
Selected Announcements | New Oriental and Yu Minhong promised to purchase a total of HK$700 million Dongfang Selected Shares; Yao Ming Joint Inc. expects adjusted net profit to increase by more than 100% last year
Saisheng Pharmaceutical: The Phase III clinical trial of Vaborem® in China completed the enrollment of all subjects; Xianruida Healthcare: The registration application for PERIDGE® was approved by the China National Drug Administration.
No Data